Navigation Links
Par Pharmaceutical's Karen O'Connor Receives 2013 Cardinal Health Supply Chain Excellence Award

WOODCLIFF LAKE, N.J., Oct. 24, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. is proud to announce that Karen O'Connor, vice president, national accounts, has received the generic pharmaceutical manufacturer 2013 Cardinal Health Supply Chain Excellence Award.  The award was presented today at Cardinal's annual Business Partners Conference in Columbus, Ohio. 

The Cardinal Health Supply Chain Excellence Award recipient is judged across a variety of metrics specifically targeted at the importance of Cardinal's generic pharmaceutical manufacturer partners.  These metrics recognize actions taken by generic suppliers to enhance service levels and create efficiencies in the supply chain, including execution on new product launches. 

"It is especially gratifying to receive an award from a highly-valued strategic partner," said Renee Kenney, senior vice president generic sales for Par Pharmaceutical.  "Both Karen and Par are honored to be recognized by Cardinal Health for our unwavering commitment to customer service.  Our efforts underscore the importance of this partnership to Par and we are proud of the trust and confidence that Cardinal has placed in us." 

Ms. O'Connor has been responsible for managing the company's relationship with Cardinal Health since joining Par in 2007.  

About Par Pharmaceutical Companies, Inc.  
Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals.  For press release and other company information, visit


SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Cellulite Study of Collegenase Clostridium Histolyticum
2. Avanir Pharmaceuticals to Host Investor Day on October 29, 2013
3. CoLucid Pharmaceuticals and ILDONG Pharmaceutical Enter into a Distribution and Supply Agreement for Lasmiditan, a Novel Agent for Acute Migraine
4. Jazz Pharmaceuticals to Report Third Quarter 2013 Financial Results on November 5, 2013
5. Norwich Pharmaceuticals is now Norwich Pharma Services
6. Hanmi Pharmaceuticals to Assign the Rights to Five New Territories to Kinex as Part of the Orascovery Program Strategic Plan
7. Avanir Pharmaceuticals Announces Enrollment of First Patient in Study of AVP-923 for the Treatment of Levodopa Induced Dyskinesia in Parkinsons Disease
8. AcelRx Pharmaceuticals to Hold Third Quarter 2013 Financial Results Conference Call and Webcast on November 5, 2013
9. Vanda Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 7, 2013
10. Global Strategic Business Radiopharmaceuticals Report 2013-2018: High Costs of Drug Development Piques Manufacturers
11. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... Maryland (PRWEB) , ... June 24, 2016 , ... ... Angels is actively feeding the Frederick area economy by obtaining investment capital for ... over the past 2½ years that have already resulted in more than a ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):